JARDIANCE® (Empagliflozin)

The content on this website is in relation to adult patients

 

Patient Profiles

JARDIANCE reduces the risk of CV death or HHF vs placebo, for your patients like Oliver and Glenda1-3

The following are fictitious characters and hypothetical scenarios.

Quick links
JARDIANCE® (empagliflozin) fictional patient profile Glenda

HFpEF Patient

Meet Glenda, 76*

Diagnosed with symptomatic chronic HFpEF

  • Experiencing HF symptoms of shortness of breath and leg swelling, with a NYHA class II progressing to class III
  • LVEF: 55%-60%
  • eGFR: 34mL/min/1.73m2

  • Beta blocker
  • Diuretic
  • ACEi

*not an actual patient

JARDIANCE® (empagliflozin) fictional patient profile Oliver

HFrEF Patient

Meet Oliver, 63*

Diagnosed with symptomatic chronic HFrEF

  • Experiencing HF symptoms of shortness of breath and leg swelling, with a NYHA class II progressing to class III
  • LVEF: 30%-35%
  • eGFR: 48mL/min/1.73m2

  • ARB
  • Diuretic
  • Beta blocker

*not an actual patient

Abbreviations

ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CV death=cardiovascular death; eGFR=estimated glomerular filtration rate; heart failure with reduced ejection fraction; HF = heart failure; HHF = hospitalisation for heart failure; HFpEF = heart failure with preserved ejection fraction; HFrEF=heart failure with reduced ejection fraction; LVEF=left ventricular ejection fraction; NYHA = New York Heart Association.

References
  1. JARDIANCE® (empagliflozin) Summary of Product Characteristics.
  2. Packer M et al. N Engl J Med. 2020;383(15):1413–1424.
  3. Anker SD et al. N Engl J Med. 2021;385(16):1451–1461.

PC-GB-108863 V2

February 2024

Reporting adverse events

Adverse events should be reported. Reporting form and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.